The Tpl-2 kinase activates the nuclear factor of activated T cells (NFAT) and induces IL-2 expression in T-cell lines. Here we show that the activation of the IL-2 promoter by Tpl-2 is inhibited by mutant signaling molecules that inhibit the mitogen-activated protein kinase (MAPK) or the calcineurin/NFAT pathways and is promoted by combinations of signaling molecules that activate these pathways. We, therefore, conclude that signals generated by the convergence of the MAPK and the calcineurin/NFAT pathway are necessary and sucient for the activation of the IL-2 promoter by Tpl-2. The activation of both the IL-2 promoter and an NFAT-driven minimal promoter were shown to depend on signals transduced by Raf1. However, it was only the IL-2 promoter whose activation by Tpl-2 was fully blocked by the dominant negative mutant MEK1S218/ 222A and the MEK1/MEK2 inhibitor PD098059. Since the activation of NFAT is MAPK-dependent these ®ndings suggested that the activation of MAPK by Tpl-2 is either independent or only partially dependent on MEK1 and MEK2. In addition, they suggested that the activation of the IL-2 promoter is under the control of not only NFAT but also a second factor whose activation is MEK-dependent. Experiments in COS-1 and EL-4 cells con®rmed both hypotheses and revealed that the second factor activated by Tpl-2 is NF-kB. While the activation of the IL-2 promoter and an NFAT-driven minimal promoter by Tpl-2 was fully blocked by the dominant negative mutant NFATD418, it was only partially blocked by the calcineurin inhibitor cyclosporin A suggesting that the Tpl-2-mediated NFAT activation is under the control of a combination of calcineurindependent and independent pathways. Both pathways were fully blocked by Bcl-2 or Bcl-X L .
Introduction
Activation of the IL-2 promoter during T cell activation depends on the activation of several obligatory transcription factors including NFAT and NF-kB. NFAT is a complex factor composed of AP1 and NFAT components (Jain et al., 1993; Northrop et al., 1993) . The NFAT component is heterogeneous and is represented by at least four protein isoforms encoded by dierent genes that are dierentially expressed in a variety of cell types. These are NFATc (NFATc1 or NFAT2), NFATp (NFATc2 or NFAT1), NFAT3 and NFATx (NFATc3 or NFAT4) . Activation and nuclear translocation of NFAT is regulated by phosphorylation. This is under the control of several serine threonine protein kinases including GSK3 and JNK2 and phosphatases including calcineurin (Shibasaki et al., 1996; Chow et al., 1997; Rao et al., 1997) . Cyclosporin A (CsA) and FK506, two immunosuppressive drugs that inhibit NFAT activation, act by blocking the activation of calcineurin and the dephosphorylation of NFAT (Schreiber and Crabtree, 1992; Clipstone et al., 1994; Clipstone and Crabtree, 1992) . Tpl-2, an oncogenic serine-threonine protein kinase Ceci et al., 1997) that is the subject of this report, transduces signals that promote NFATp activation perhaps by inducing dephosphorylation of the protein (Tsatsanis et al., 1998) .
NFAT isoforms expressed in dierent tissues regulate the expression of cytokine genes. In the hematopoietic system, NFAT contributes to the activation of several cytokines and other early response genes including IL-2, IL-3, IL-4, IL-5, IL-8, IL-13, GM-CSF, IFN-g, TNF-a, CD40 ligand and Fas ligand . In addition to its role in cytokine gene expression, NFAT interacts directly with the cell cycle and apoptotic machineries. Thus, activation of NFAT promotes both the progression from G1 to S as well as apoptosis. Overexpressed Bcl-2 interacts with calcineurin and inhibits NFAT activation (Linette et al., 1996) , while overexpression of Bax, a pro-apoptotic member of the Bcl-2 family of proteins, reverses the eect of Bcl-2 by blocking its interaction with calcineurin (Shibasaki et al., 1997) .
The induction of IL-2 expression following T cell stimulation depends on the activation of not only NFAT but also NF-kB, another complex transcription factor that contributes to lymphocyte activation and cytokine gene expression (Jain et al., 1995) . NF-kB represents a protein family whose members include p65(RelA), c-Rel, RelB, p50(NF-kB1) and p52 (NFkB2) . Some of these proteins, such as p50 and p52, are expressed as inactive precursors (p105 and p100, respectively) that are localized primarily in the cytosol (Thanos and Maniatis, 1995; Baeuerle and Baltimore, 1996) . Potentially active NF-kB proteins are also localized primarily in the cytosol bound to a family of inhibitory proteins (Ik-Ba, Ik-Bb, Ik-Bg and Ik-Be) (Beg and Baldwin, 1993, Simeonidis et al., 1997) . NFkB activation signals induce proteolytic cleavage of the precursor proteins or lead to the degradation of the inhibitory Ik-B molecules (Chen et al., 1995) . The released active NF-kB molecules translocate to the nucleus and bind DNA as homodimers or heterodimers (Fujita et al., 1992) .
Tpl-2 is a serine-threonine protein kinase that is activated by carboxy-terminal truncation during progression of MoMuLV induced T cell lymphomas and MMTV-induced mammary carcinomas Makris et al., 1993; Ceci et al., 1997; Erny et al., 1996) . Earlier studies had shown that Tpl-2 transduces signals that activate the MAPKinase and the SAPKinase cascades (Ceci et al., 1997; Patriotis et al., 1994; Salmeron et al., 1996) . More recent studies revealed that Tpl-2 activates NFAT in various cell types (Tsatsanis et al., 1998) and induces IL-2 expression when transfected in EL4 and Jurkat cells (Ballester et al., 1997; Tsatsanis et al., 1998) . The Tpl-2-dependent pathway leading to the activation of the IL-2 promoter in these cell lines can be triggered by TCR stimulation (Tsatsanis et al., 1998) .
In this report we show that the activation of NFAT and the IL-2 promoter by Tpl-2 depends on the convergence of calcineurin/NFAT and MAPK activation signals induced by Tpl-2. The activation of NFAT is under the control of a combination of calcineurindependent and calcineurin-independent pathways, both of which are blocked by Bcl-2 and Bcl-X L . Activation of the IL-2 promoter but not of the NFAT-driven minimal promoter is fully blocked by inhibitors of MEK1 and MEK2. Evidence presented in this report shows that the dierence between the two promoters is due to a combination of factors: a) the activation of the MAPK by Tpl-2 is at least in part MEK1/MEK2 independent and b) Tpl-2 also activates NF-kB, another transcription factor that plays an obligatory role in IL-2 induction, via a MEK1/MEK2 dependent mechanism.
Results
Dominant negative mutants inhibiting the MAPK and the calcineurin/NFAT pathways block the Tpl-2 mediated activation of the IL-2 promoter
We had previously shown that Tpl-2 induces IL-2 expression in EL4 and Jurkat cells. Moreover, we had shown that Tpl-2 activates NFAT, a complex transcription factor composed of NFAT and AP1 components, whose activation is obligatory for IL-2 induction (Jain et al., 1992; Luo et al., 1996; Northrop et al., 1993; Rooney et al., 1995) . Since Tpl-2 activates NFAT as well as the MAPK pathway (Ceci et al., 1997; Tsatsanis et al., 1998) , which is required for the activation of AP1 (Jain et al., 1993) , we examined whether dominant negative mutants of several proteins transducing signals along these pathways inhibit the activation of the IL-2 promoter by Tpl-2. To this end, EL4 cells were cotransfected with an IL-2 promoter/ CAT reporter construct, a Tpl-2 expression construct and expression constructs of the dominant negative (DN) mutants Ha-ras N17, MEK1S218/222A, Raf1S621A and NFATcD418. The results showed that these dominant negative mutants block the Tpl-2 mediated induction of the IL-2 promoter ( Figure 1 ) and suggested that the activation of the IL-2 promoter by Tpl-2 depends on the convergence of the MAPK and the calcineurin/NFAT pathways. Additional experiments in the following two paragraphs provide support for this conclusion.
Wild-type Tpl-2 activates the IL-2 promoter and an NFAT-driven promoter in Jurkat cells only when co-expressed with activated calcineurin
We had previously shown that EL4 cells express IL-2 following transfection of either the wild-type or the oncogenic carboxy-terminally truncated Tpl-2 constructs (Tsatsanis et al., 1998) . On the other hand, Jurkat cells express IL-2, only in response to carboxyterminally truncated Tpl-2. Since EL4 cells express a mutant calcineurin (CnAD477N) which is more sensitive to¯uctuations in the concentration of cytoplasmic calcium (Fruman et al., 1995) , we hypothesized that the enhanced sensitivity of EL4 cells to Tpl-2 may be due to the partially activated calcineurin in these cells. To test this hypothesis Jurkat cells were transfected with wild-type or truncated Tpl-2 constructs alone or in combination with the activated form of calcineurin, DCnA, and the expression of IL-2 was monitored using an ELISA assay (Figure 2a) . Alternatively, the same combinations of expression constructs were cotransfected with the IL-2/CAT reporter construct and the activity of the IL-2 promoter was monitored by measuring CAT enzymatic activity in transfected cell lysates (Figure 2b , samples 1 ± 4). The results con®rmed the proposed hypothesis by showing that both the endogenous IL-2 promoter and the transiently transfected IL-2/CAT reporter were activated in Jurkat cells cotransfected with expression constructs of the wild-type Tpl-2 and the activated calcineurin but not wild-type Tpl-2 alone Figure 1 Activation of the IL-2 promoter by Tpl-2 is inhibited by dominant inhibitory mutants of the MAPK and the calcium/ calcineurin NFAT pathways. EL4 cells were cotransfected with Tpl-2, the IL-2/CAT reporter construct and the indicated constructs of dominant negative mutants. The indicated cultures were treated with PMA and ionomycin 36 h after transfection. CAT activity was measured in the cell lysates and was quantitated by phospho-imager. Transfections were carried out in quadruplicate and expression was normalized based on the expression of b-Gal from a cotransfected CMV5/b-Gal construct Tpl-2 activates NFAT and NF-kB C Tsatsanis et al (Figure 2b , samples 2 and 3). Identical results were obtained when, instead of the IL-2/CAT construct, a reporter construct utilizing an NFAT-driven minimal promoter (NFAT/CAT) was used ( Figure 2b , samples 5 ± 8).
The combined activation of the MAPK and calcineurin/ NFAT pathways by Raf1Y340D and NFATp, NFATc or DCnA activates the NFAT-driven minimal promoter
Tpl-2 as well as v-Ha-ras activated the NFAT-driven minimal promoter in EL4 cells while Raf1Y340D, a potent activator of the MAPK pathway as well as the activators of the NFAT pathway NFATc, NFATp, NFATx, DCnA and CAML failed to do so ( Figure 3 ). These ®ndings con®rmed that the activation of neither the MAPK nor the calcineurin/NFAT pathway alone is sucient to activate the NFAT-driven promoter. To test whether the concerted activation of the two pathways activates the NFAT-driven promoter, EL4 cells were cotransfected with the reporter NFAT/CAT construct and expression constructs of Raf1Y340D and each of the listed activators of the NFAT pathway.
The results con®rmed that the synergistic action of Raf1Y340D and NFATc, NFATp or DCnA is sucient to activate the NFAT-driven minimal promoter ( Figure 3 , samples 4, 6 and 12). Therefore, the activation of NFAT by Tpl-2 is due to the combined activation of these pathways both of which are known to be induced by Tpl-2 (Tsatsanis et al., 1998) .
Cyclosporin A inhibits partially while Bcl-2 and Bcl-X L inhibit fully the Tpl-2-mediated activation of NFAT
CsA is an immunosuppressant that inhibits IL-2 expression by blocking the calcineurin-mediated activation of NFAT induced by phorbol esters and ionomycin. Treatment of the Tpl-2 transfected EL4 cells with CsA only partially blocked activation of the IL-2 and the NFAT-driven minimal promoter ( Figure 4a , sample 3 and Figure 4b , samples 7 and 9). This ®nding which was unexpected given the profound inhibition of both promoters by the dominant negative mutant NFATcD418 ( Figure 1 , sample 7 and Figure 5 , sample 7) suggests that Tpl-2 acts through both CsA-sensitive and CsA-insensitive pathways to activate NFAT. A CsA insensitive pathway which is activated by PMA and CD28 co-stimulation has been previously reported (Ghosh et al., 1996) . This pathway activates NFATp Transfections were carried out in quadruplicate. Fortyeight hours later the cells were harvested and CAT activity was measured in the lysates. Activity was quantitated by phosphoimager
Tpl-2 activates NFAT and NF-kB C Tsatsanis et al which is also selectively activated by Tpl-2 (Tsatsanis et al., 1998) .
Evidence presented in Figure 4b shows that v-HaRas, similar to Tpl-2, is sucient to activate NFAT in EL-4 cells. Moreover, the dominant negative mutant Ha-RasN17 blocks the Tpl-2-mediated activation of NFAT ( Figure 5 , sample 3). Interestingly, while the activation of NFAT by Tpl-2 is only partially blocked by CsA (Figure 4b , sample 7) the activation of NFAT by v-Ha-Ras is fully blocked by this inhibitor ( Figure  4b , sample 3). These ®ndings suggest that the activation of the calcineurin/NFAT pathway by Tpl-2 depends on a combination of Ras-dependent and independent signals. The Ras-independent signal is not inhibited by CsA and therefore operates downstream of calcineurin.
Co-expression of Tpl-2 with Bcl-2 or Bcl-X L but not Mcl-1 fully inhibited the Tpl-2-induced NFAT activa- Figure 4 (a) Tpl-2 -induced activation of the IL-2 promoter is only partially inhibited by CsA. EL4 cells were cotransfected with a Tpl-2 expression construct and an IL-2/CAT reporter plasmid and 24 h after transfection were treated with CsA. (b) Tpl-2 and vHa-ras activate the NFAT/SV40 promoter but v-Ha-ras-mediated activation is inhibited fully, while Tpl-2-mediated activation is inhibited only partially by cyclosporin A (CsA). EL4 cells were cotransfected with v-Ha-ras or Tpl-2 (wild-type or truncated) and the NFAT/CAT reporter construct. Transfected cells were treated with CsA as indicated. Control cultures were treated with PMA and ionomycin with or without CsA, also as indicated. CsA was added at 24 h following transfection and PMA and ionomycin at 36 h following transfection. Cells were harvested at 48 h following transfection. CAT activity was measured in the cell lysates and was quantitated by phospho-imager. Transfections were carried out in quadruplicate. Expression was normalized based on the expression of b-Gal from a cotransfected CMV5/b-Gal construct. (c) Activation of NFAT by Tpl-2 is inhibited by Bcl-2 and Bcl-X L but not by Mcl-1. EL4 cells were co-transfected with Tpl-2 and the corresponding expression constructs and the NFAT/CAT reporter plasmid. CAT activity was measured as described. Each bar represents the average of triplicate samples. The experiment was repeated at least three times Tpl-2 activates NFAT and NF-kB C Tsatsanis et al tion (Figure 4c ). These ®ndings suggest that Bcl-2 and Bcl-X L inhibit both signals. Similarly, activation of NFAT by PMA and ionomycin was fully blocked by Bcl-2 and Bcl-X L but not Mcl-1 (Figure 4c ). Earlier studies had shown that Bcl-2 binds calcineurin A at the catalytic domain and sequesters it at the plasma membrane, thus preventing it from dephosphorylating NFAT (Shibasaki et al., 1997) . The mechanism by which Bcl-2 and Bcl-X L block the signal operating downstream of calcineurin remains unknown.
The dominant negative mutant MEK1S218/222A blocks the activation of the IL-2 promoter but not the NFATdriven promoter by Tpl-2
The experiment on the regulation of the IL-2 promoter/CAT reporter shown in Figure 1 was repeated with the NFAT/CAT reporter construct. The pattern of inhibition of the NFAT-driven promoter by the dominant negative mutants shown in Figure 5 was identical to the pattern of inhibition of the IL-2 promoter by the same mutants with the exception of MEK1S218/222A which inhibited fully the Tpl-2-induced activation of the IL-2 promoter but only partially the activation of the NFAT-driven promoter. Similar results were obtained using the MEK1/MEK2 inhibitor PD098059 (Parke-Davis Pharmaceuticals) (data not shown). Since the activation of NFAT is MAPK-dependent these ®ndings suggest that the Tpl-2-mediated activation of MAPK is, at least partially, independent of MEK1 or MEK2.
Tpl-2 activates the MAPK ERK1 via a MEK1-independent pathway
To test the hypothesis that the activation of the MAPK by Tpl-2 is MEK1-independent we examined whether MEK1 is required for the activation of the MAPK ERK1 by Tpl-2 in COS-1 cells. Overexpression of the dominant negative mutant MEK1S218/222A inhibited minimally the activation of ERK1 by Tpl-2 while it inhibited fully the activation of ERK1 by EGF. Similar results were obtained when the cells were treated with the MEK1/MEK2 inhibitor PD098059 (Figure 6 ). This observation con®rmed that Tpl-2 activates the MAPK and showed that the activation of MAPK by Tpl-2 is at least in part MEK1/MEK2-independent.
Tpl-2 activates NF-kB by a MEK-dependent mechanism. NF-kB activation is required for Tpl-2-mediated activation of the IL-2 promoter
The dierence between the IL-2 and NFAT promoters regarding their induction by Tpl-2 in the presence or absence of MEK1S218/222A suggests that Tpl-2 may regulate the activity of additional transcription factors that contribute to the activation of the IL-2 promoter and are activated via a MEK1/MEK2-dependent mechanism. Activation of the IL-2 promoter relies on the simultaneous activation of the transcription factors NFAT, AP1, NF-kB and Oct (Figure 7a ) (Garrity et al., 1994; Rooney et al., 1995) . Of these, NFAT and NF-kB are obligatory for the activation of the IL-2 promoter. Thus, mutation of the NF-kB binding site or one of the NFAT sites of the IL-2 promoter blocked its responsiveness to either Tpl-2 or PMA and ionomycin (Figure 7b) . Moreover, overexpression of Ik-Ba inhibited the Tpl-2 mediated activation of the IL-2 promoter (Figure 7c) .
We therefore tested whether Tpl-2 activates NF-kB, and whether the potential activation of this factor is MEK-dependent. The data in Figure 7d revealed that Tpl-2 indeed activates NF-kB in EL4 cells and that the dominant negative mutants MEK1S218/222A, Ha-Ras Figure 5 Activation of the NFAT/CAT reporter by Tpl-2 was inhibited by dierent dominant inhibitory mutants of the MAPK and the Calcineurin/NFAT pathways. EL4 cells were transiently cotransfected with Tpl-2 expressing construct, the corresponding expression plasmid of the dominant negative mutant and an NFAT/CAT reporter plasmid. Transfections were carried out in quadruplicate. Forty-eight hours later the cells were harvested and CAT activity was measured in the lysates. Activity was quantitated by phospho-imager Figure 6 Activation of the MAPK by Tpl-2 is ERK1 independent. COS-1 cells were co-transfected with HA-tagged ERK1 and wild-type Tpl-2 as indicated. Cells were stimulated with EGF1 where indicated. ERK1 kinase activity was measured in the immunoprecipitate (panel I). The p44ERK1 (panel II), Tpl-2 (panel III) and MEK1S218/222A (panel IV) protein expression was measured in the total lysate Tpl-2 activates NFAT and NF-kB C Tsatsanis et al Figure 7 (a) Diagrammatic representation of the IL-2 promoter. The binding sites noted with an asterisk were mutated in the corresponding constructs. (b) Mutation of the NF-kB or NFAT binding sites on the IL-2 promoter abolishes its ability to be activated either by Tpl-2 or by PMA and ionomycin. EL4 cells were transfected with wild-type or truncated Tpl-2 and the corresponding mutant promoters. Cells were harvested 48 h after transfection and CAT activity was measured in the cell lysates as described in Materials and methods. Where indicated cells were stimulated with PMA and ionomycin 8 h prior to harvesting. (c) IkBa overexpression inhibits the Tpl-2 mediated activation of the IL-2 promoter. EL4 cells were transfected with Tpl-2 and the wildtype Ik-Ba expression constructs and an IL-2/CAT reporter construct. CAT activity was measured as described. Transfection eciency was monitored by expression of b-Gal. (d) NF-kB activation by Tpl-2 is MEK1, Ha-Ras and Raf1 dependent. EL4 cells were transfected with Tpl-2 and the dominant negative mutants MEK1S218/222A, Ha-Ras N17, Raf1 S621A and a CAT reporter construct containing 6 NF-kB binding sites upstream the TK minimal promoter. CAT activity was measured as described Tpl-2 activates NFAT and NF-kB C Tsatsanis et al N17 and Raf1S621A block its activation. We conclude that Tpl-2 activates NF-kB in a MEK1-dependent and NFAT in a MEK1-independent fashion.
Discussion
In the present study we examined the pathways through which Tpl-2 activates NFAT and induces expression of IL-2 in lymphoid cell lines. The results show that the activation of both the IL-2 promoter and an NFAT regulated basal SV40 promoter by Tpl-2 is mediated by the MAPK pathway in combination with the calcium dependent calcineurin/NFAT pathway. Inhibition of the MAPK or the calcineurin pathway abrogated IL-2 and NFAT promoter activation by Tpl-2. These ®ndings led us to propose the model of NFAT and IL-2 promoter activation by Tpl-2 shown in Figure 8 . This model takes into account the fact that NFAT is a complex factor composed of AP1 and NFAT components (Northrop et al., 1993) . Activation of the MAPK by Tpl-2 according to this model occurs through at least two distinct signals, one that is MEKdependent and one that is MEK-independent. Both the MEK-dependent and independent signals are transduced via Ha-ras and Raf1. Therefore, Tpl-2 signals activating the MAPK diverge downstream of Raf1. Tpl-2 also initiates signals that activate NFAT (Tsatsanis et al., 1998) . These signals are inhibited by cyclosporin only partially, suggesting that Tpl-2 operates both upstream and downstream of calcineurin. The same signals are fully blocked by Bcl-2 and Bcl-X L . Combination of the above signals leads to the activation and nuclear translocation of NFAT and NFkB, two transcription factors, that are obligatory for the activation of the IL-2 promoter. According to this model, NFAT is activated via the convergence of the MAPK pathway that contributes to the activation of the AP1 component of NFAT, and the calcineurin NFAT pathway. The lack of inhibition of the activation of the IL-2 and the NFAT promoter by the dominant negative mutant SEK1K299R suggests that the contribution of the SAPK pathway may not be critical for the activation of NFAT by Tpl-2. Alternatively, SAPK may be activated by pathways (Su et al., 1994) that are SEK1-independent. Activation of the NFAT-regulated minimal promoter in EL4 cells following transient transfection of activated Raf1 (Raf1Y340D) and activated calcineurin (DCnA) or activated NFATc provided support to this model. Additional support was provided by experiments comparing the activation of the IL-2 promoter and the NFAT-regulated minimal SV40 promoter in EL4 and Jurkat cells. Data presented here show that the carboxyterminally truncated Tpl-2 activates NFAT in both cell lines, while the wild-type Tpl-2 activates NFAT only in EL4 cells. Since the EL4 cells express a mutant calcineurin (CnA D477N) which exhibits enhanced sensitivity to increases in the cytoplasmic calcium levels, and is therefore partially activated (Fruman et al., 1995) , we hypothesized that the enhanced responsiveness of EL4 cells to Tpl-2 is due to the lower threshold for the activation of calcineurin in these cells. To address this hypothesis, we cotransfected Jurkat cells with wild-type Tpl-2 in combination with an expression construct of an activated mutant of calcineurin (DCnA). The results provided support for the model by showing that the combination of the two activates NFAT and induces IL-2 expression.
According to the model in Figure 8 , Ras plays a central role in the activation of NFAT by Tpl-2. Data presented here indeed show that Ha-ras-N17, a dominant negative mutant of Ha-ras, blocks Tpl-2-induced NFAT activation. In addition, Raf1S621A, a dominant negative mutant of Raf1, which inhibits the Tpl-2-and v-Ha-ras-induced activation of the MAPK (Patriotis et al., 1994) , also inhibits the Tpl-2-induced activation of the IL-2 and NFAT promoters (Figure 1  and 4) . However, Raf1Y340D, an active form of Raf, activated the MAPK pathway (Patriotis et al., 1994) but failed to activate NFAT and the IL-2 promoter (Figure 2 and data not shown). Therefore, Raf1 is required but it is not sucient to drive the NFAT or the IL-2 promoters, indicating that Ras needs additional eectors that activate calcineurin to initiate transcription from these promoters.
Although CsA fully blocks the activation of NFAT by v-Ha-ras it only partially inhibits the activation of NFAT by Tpl-2. This suggests that Tpl-2 may activate NFAT via Ras-dependent signals that activate calcineurin and through Ras-independent signals that function downstream of calcineurin. Both Bcl-2 and Bcl-X L fully block the Tpl-2-mediated NFAT activation. We therefore conclude that Bcl-2 and Bcl-X L block both NFAT activation pathways triggered by Tpl-2 and not only the activation of calcineurin as originally suggested (Shibasaki et al., 1997) . Bcl-2 binds the catalytic domain of calcineurin through its BH4 domain, suggesting that it may also bind a related phosphatase that dephosphorylates NFAT and is CsAresistant. The BH4 domains of Bcl-2 and Bcl-X L share high homology in contrast to the BH4 domain of Mcl-1 which is more distant (Sato et al., 1994) . Therefore, it is possible that Bcl-X L and Mcl-1 may dier in their ability to bind the catalytic domain of calcineurin. The calcineurin-independent pathway of NFAT activation may be the same as the one originally proposed by (Ghosh et al., 1996) . Figure 8 Model of Tpl-2 mediated activation of NFAT and NFkB. The activation of NFAT and NF-kB can be induced either by TCR stimulation or pharmacologically using ionomycin, which stimulates calcium in¯ux, and PMA which activates PKC. Tpl-2 transduces some of these signals leading to the activation of NFAT and NF-kB Tpl-2 activates NFAT and NF-kB C Tsatsanis et al Experiments presented in this report revealed that the Tpl-2-mediated activation of the IL-2 promoter also depends on the activation of NF-kB, which is mediated by a MEK1 dependent mechanism. Although there is no published direct evidence to date that MEK1 is involved in the activation of NF-kB, recent studies have shown that Raf1, the activator of MEK1, activates NF-kB perhaps by contributing to the phosphorylation and proteolytic degradation of Ik-Ba (Lee et al., 1997) . The investigation of the role of Tpl-2 in NF-kB activation was triggered by the surprizing ®nding that inhibition of MEK1 and MEK2 blocked the Tpl-2-induced activation of the IL-2 promoter, but had no eect on the Tpl-2-mediated activation of the NFAT-driven minimal promoter. Since the activation of NFAT depends on the activation of the MAPK pathway this ®nding suggested that the Tpl-2-mediated activation of the MAPK is MEK1-independent. In addition, it suggested that the activation of the IL-2 promoter by Tpl-2 depends on the MEK-dependent activation of another obligatory pathway. The data presented in this report con®rmed both hypothesis and demonstrated that the MEK-dependent pathway that is activated by Tpl-2 and contributes to the activation of the IL-2 promoter is the NF-kB activation pathway. The MEK-dependence of the Tpl-2-mediated activation of the MAPK pathway was examined in transiently transfected COS-1 cells. The Tpl-2-mediated activation of the MAPK ERK1 in these cells was mainly MEK1-independent. However, since Tpl-2 phosphorylates MEK1 in vitro (Salmeron et al., 1996) , the Tpl-2-induced MAPK activation may be transduced, at least in part, via MEK1.
The activation of NF-kB by Tpl-2 was not surprizing. The sequence of the Tpl-2 kinase domain suggests that Tpl-2 is a member of the family of MAP3Kinases that includes MEKK1 Ichijo et al., 1997 , Malinin et al., 1997 . Earlier studies had shown that MEKK1 and the related NFkB-inducing kinase (NIK) associate with and activate the large molecular weight complex that phosphorylates Ik-B (Lee et al., 1997 , DiDonato et al., 1997 , Mercurio et al., 1997 . More recent studies have shown that indeed MEKK1 as well as NIK phosphorylate and activate the Ik-B kinases IKKa and IKKb (Lee et al., 1998; Karin and Delhase, 1998) . Based on these observations and our data we suggest that Tpl-2 may also phosphorylate the Ik-B kinases. The multiplicity of kinases that may be able to activate the Ik-B kinases suggests that each of them may be involved in the transduction of some but not all NF-kB activation signals. Since these kinases are multifunctional in that Tpl-2 also activates both the MAPK and the SAPK pathways (Ceci et al., 1997; Patriotis et al., 1994; Salmeron et al., 1996) , MEKK1 activates the SAPK pathway (Yan et al., 1994) and NIK activates neither, their selective utilization by dierent signals can provide signi®cant speci®city to the cellular response. If Tpl-2 is involved in the phosphorylation of the Ik-B kinases, the role of MEK1/MEK2 suggested by our ®ndings is not currently clear. One possibility is that MEK1/MEK2 plays an intermediate role in this process and provides a complimentary signal.
Overall, the data presented in this report show that Tpl-2, a proto-oncogene associated with tumor progression in retrovirus induced rodent T-cell lymphomas activates multiple signaling pathways. The activation of NFAT and NF-kB and the induction of IL-2 in T cells through these pathways suggests that Tpl-2 may play an important role in T cell activation and de®nes a potential molecular mechanism that may contribute to its oncogenic potential.
Materials and methods

Cells and cell culture
EL4 cells (EL4.IL-2, obtained from ATCC) were cultured at 378C and 5% CO 2 in DMEM supplemented with 10% horse serum (HS) and Penicillin (50 IU/ml), Streptomycin (50 mg/ml) and Kanamycin (100 mg/ml) (PSK). Jurkat cells (clone 6.1 from ATCC) were also cultured at 378C and 5% CO 2 in RPMI-1640 supplemented with 10% (v/v) fetal bovine serum (FBS) and PSK. EL4 and Jurkat cells were treated with phorbol 12-myristate 13-acetate (PMA) (10 nM) and ionomycin (2 nM) for 8 h for IL-2 or NFAT induction. Cyclosporin A, an immunosuppressive agent that inhibits calcineurin, was added in some cultures at 100 ng/ml, PD098059, an inhibitor of MEK1 and MEK2 provided by Dr A Saltiel (Parke Davis Pharmaceuticals) was also added at 50 mM where indicated.
Plasmids
The reporter plasmid IL-2/CAT (15deltacxCAT) containing the initiation site of the IL-2 promoter and 326 bps of upstream sequences (Durand et al., 1988) was provided by Dr G Crabtree (Stanford University Med. School, Palo Alto, CA, USA). The reporter construct pSPNFAT/CAT, containing three NFAT binding sites (AGAAAGGAG-GAAAAACTGTTTCATACAGAAGGCGTT) upstream of the SV40 minimal promoter (Thompson et al., 1992) was provided by Dr C Thompson (University of Chicago). The mutant IL-2/CAT constructs were generated by overlap extension PCR using oligonucleotides containing mutations in the following sites: NFAT site at 7280 (AGGAGGAA changed to ACGTCCTA); NF-kB site at 7205 (AAGAGGGATTT changed to AGGATTGATGT); and NFAT-like CD28RE site at 7l60 (GGTTTAAAGA changed to GCTCTTACCA). The wild-type Ik-Ba expression construct and the reporter plasmid NF-kB/CAT which consists of six NF-kB binding sites upstream the thymidine kinase (TK) minimal promoter and a CAT reporter gene, were provided by Dr J Caamano (Bristol Myers Squibb). The constitutively active mutant calcineurin pSRaDCnA (Frantz et al., 1994) was provided by Dr E O'Neill (Merck Sharp and Dohme, Rahway, NJ, USA), NFAT c (pSH102) and the dominant negative DNFAT c (pSH102CD418) constructs (Northrop et al., 1994) were provided by Dr G Crabtree. The dominant negative MEK1 mutant (MEK1S218/222A) (Pang et al., 1995) was provided by Dr A Saltiel (Parke Davis Pharmaceuticals, Ann Arbor, MI, USA), the wild-type and the kinase inactive SEK-1 mutant (SEK1 K 299 R) (Sanchez et al., 1994) were provided by Dr J Cherno (Fox Chase Cancer Center). Activated Raf1 (Raf1Y340D) and the dominant inhibitory Raf1 mutant (Raf1S621A) were provided by Dr D Morrison (Morrison et al., 1989 ) (NCI, FCRDC, Frederick, MD, USA). Finally, the calmodulin modulating ligand (CAML) expression plasmid (Bram and Crabtree, 1994) was provided by Dr R Bram (St. Jude's Children's Hospital, Memphis, TN, USA). The Bcl-2 and Bcl-X L expression plasmids were provided by Dr S Korsmeyer (Washington University) and the Mcl-1 expression plasmid by Dr D Craig (Dartmouth University). ) were transiently transfected by electroporation (260 mV, 940 mF) and harvested 44 h later. Cells were stimulated with PMA and ionomycin 8 h prior to harvesting, or they were treated with CsA or PD098059 24 h prior to harvesting, where indicated. Transfections were carried out using 8 mg IL-2/CAT, 5 mg NF-kB/CAT or 6 mg pSPNFAT/CAT reporter constructs in combination with 2.5 mg of each expression construct (5 mg total). In cases where one expression construct was used 2.5 mg of CMV5 empty vector was added to bring the total amount of vector DNA containing the CMV promoter to 6 mg per transfection including 1 mg of CMV-b-Galactosidase (CMV-b-Gal) plasmid. pBluescript was added to bring the total amount of electroporated DNA to 20 mg. Beta galactosidase expression was measured as described (Bignon et al., 1993) and samples were normalized for equal levels of expression. Each transfection was carried out in quadruplicate and every experiment was repeated at least twice. Chloramphenicol acetyl transferase (CAT) assays were performed as previously described (Zweidler et al., 1996) . The acetyl transferase reaction was carried out for 3 h. The acetylated and the non-acetylated forms of 14 C-chloramphenicol (Amersham) were separated on TLC plates (Sigma). Chloramphenicol acetylation was quantitated using Fuji phosphor-imager and Fuji Mac-bas V2.2 software.
Immunoprecipitation and in-gel kinase assay
Cells were washed with ice-cold PBS and they were lysed on ice for 20 min in 0.5 ml of an NP-40 lysis buer (20 mM Tris Cl, pH 8.0, 137 mM NaCl, 0.5% (v/v) Nonidet P-40, 10% (v/v) glycerol, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethyl-sulfonyl¯uoride, 2.5 nM okadaic acid (Sigma) 0.5 mM dithiothreitol, 16 complete protease inhibitors (Boehringer-Mannheim)). The cell lysates were clari®ed by centrifugation at 12 000 g at 48C for 10 min. Subsequently, they were precleared by incubation with 20 ml of a 50% suspension of protein A/protein G (1 : 1)-agarose (Gibco ± BRL) for 30 min at 48C. Following removal of the agarose beads by centrifugation at 12 000 g at 48C for 10 min, the precleared lysates were incubated for 3 h at 48C with the anti-HA antibody (HAû11) (1/250 dilution), in the presence of 40 ml 50% protein A/protein G (1 : 1)-agarose. The immunoprecipitate/agarose bead complexes were collected by centrifugation at 6 000 g for 2 min at 48C, and they were washed, also at 48C, three times with 1 ml lysis buer and twice with 1 ml kinase wash buer containing 20 mM HEPES, pH 7.5, 5 mM MgCl 2 and 1 mM dithiothreitol.
In-gel kinase assays were carried out as previously described (Patriotis et al., 1994) . Brie¯y, pelleted immunoprecipitates were electrophoresed in SDS 10% polyacrylamide gel containing myelin basic protein (MBP, Sigma) at 0.25 mg/ml. Subsequently the gel was treated with several changes of 50 mM Tris HCl (pH 8.0) in 20% isopropyl alcohol for 1 h and for an additional hour with 50 mM Tris HCl/6M guanidinium chloride/5 mM beta mercaptoethanol. The gel was then incubated at 48C for 16 h in Tris HCl (pH 8.0)/0.04% (v/v) Tween 20/5 mM beta mercaptoethanol. Subsequently the gel was equilibrated for 30 min in kinase buer (40 mM HEPES, pH 8.0/ 2 mM dithiothreitol/ 0.1 mM EGTA/ 5 mM magnesium acetate). Finally, the gel was incubated for 1 h in kinase buer containing 20 mM ATP and 150 mCi [g-32 P]ATP (Amersham; 3000 Ci/mmol). The unincorporated ATP was removed by washing for 2 ± 2.5 h with several changes of 5% (w/v) trichloroacetic acid 1% (w/ v) sodium pyrophosphate. The gel was then dried and exposed to XAR ®lm (Kodak).
Immunoblotting SDS ± PAGE and electroblotting were carried out as previously described (Patriotis et al., 1994) . The antibodies and the dilutions at which they were used were as follows: anti-HA tag (HA.11, BaBco) (1/1000 dilution), anti-Tpl-2 (PT492 rabbit polyclonal) (1/1000 dilution), anti-MEK1 (SC-219, Santa Cruz) (1/1000 dilution). Excess antibody was removed by two 10 min and three 5 min washes in PBS containing 0.1% (v/v) Tween-20. Antigen-bound antibody was detected by a 60 min room temperature incubation in a 1/5000 dilution of the corresponding secondary antibody conjugated with horseradish peroxidase (Amersham). The unbound secondary antibody was removed using the same washing procedure we used to remove the excess primary antibody with three additional 10 min washes in PBS. The binding of the secondary antibody was detected by enhanced chemiluminescence (ECL, Amersham). Immunoblots were exposed to Re¯ection NEF ®lm (NEN, DuPont) for 1 ± 10 min.
